Clinical Trials

2 studies in Bladder Cancer

1. Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB Rochester, MN View Summary
   Close

   Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   A previously completed pivotal clinical study PC B305/04 demonstrated reduced recurrence rates for patients with papillary bladder cancer who underwent Hexvix (Cysview) and white light cystoscopy and transurethral resection (TURB) of the bladder compared to patients who underwent white light cystoscopy and TURB alone. The present study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will also lead to a longer-term reduction in recurrences compared to standard white light cystoscopy/TURB.

   NCT ID:

   NCT01166230

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   - Mayo Clinic Cancer Center - Phone: 507-538-7623 - Research Volunteer Program - Phone: 1-800-664-4542 (toll-free) Email: clinicaltrials@mayo.edu - International Research - Phone: 507-284-8884 Email: intl.mcr@mayo.edu

   Request Information Online
2. Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer Rochester, MN View Summary
   Close

   Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Criteria for Evaluation: Efficacy: A Response is defined as no evidence of recurrence of a high grade tumor by cystoscopy, cytology or if clinically indicated, biopsy. Safety: The safety and tolerability of INSTILADRIN will be evaluated based on adverse event reports, vital signs, ECGs, clinical laboratory values and results of physical examination.

   NCT ID:

   NCT01687244

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Stephen Boorjian, MD 507-284-3982
                       Jane Smith, RN, BSN, CCRP 507-284-3369
   
   
   

   Request Information Online